Traxion Sab De Cv Ord Shs GRPOF

RE:RE:RE:RE:Not seeing the bounce to $1 are we, need more than luck!

[stocktickler87]

I will never thank you lol. You are actually delusional enough to think your words have any credibility here you flip flopping fish. Flush...

LeafRider wrote: Well our competitor isn't exactly selling the sox off Dronabinol at the moment see for yourself. So your projections for PPP002 revenue don't exactly scream BUY BUY BUY. Do you honestly think Tetra will see revenue from PPP002 in 2019? If you believe that, that is part of your problem. Keep eating the BS they keep feeding you pretty soon you'll wonder why your eyes are brown, and that's because you're full of $hit!

All this hype around what Tetra has in the hopper, what hype? There is none asside from the few pumpers left on this stock. You guys will thank me later, don't worry, I'm here for Hammerhad and Pumper4Life to help them look past the tip of their nose.

Net revenue included $30.7 million from Subsys and $800,000 from Syndros, a liquid dronabinol that Insys launched in mid-2017 to treat anorexia in people with AIDS who have lost weight, and vomiting associated with chemotherapy.

Link: https://www.reuters.com/article/us-insys-results/drugmaker-insys-loss-widens-on-lower-subsys-sales-idUSKCN1GK306

Hammertown87 wrote: I think someone hacked his account because he should know this which is coming in 2019.

In the autumn of 2018 Tetra held a Type B meeting with the FDA for the dronabinol AdVersa™ mucoadhesive delivery system, PPP002. Tetra, along with its partner IntelGenx Corp, is developing this product in the United States under the accelerated 505(b)(2) pathway for the indication of chemotherapy-induced nausea and vomiting, and anorexia and weight loss in people with AIDS. The FDA confirmed the eligibility of the 505(b)(2) regulatory pathway for the product PPP002 and that the efficacy and systemic safety would be supported by the corporation’s proposed comparative bioavailability study and, if successful, Tetra could apply for FDA approval in late 2019, for those indications.